Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

BACKGROUND Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness. METHODS Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection. RESULTS In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro. CONCLUSIONS gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).

[1]  M. Unemo,et al.  Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.

[2]  Hong Wu,et al.  Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections , 2011, Front. Microbio..

[3]  Stuart Berman,et al.  Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[4]  Vanessa G. Allen,et al.  Molecular Analysis of Antimicrobial Resistance Mechanisms in Neisseria gonorrhoeae Isolates from Ontario, Canada , 2010, Antimicrobial Agents and Chemotherapy.

[5]  Sebastian Bonhoeffer,et al.  Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations , 2010, Antimicrobial Agents and Chemotherapy.

[6]  S. Porwollik,et al.  Fitness Costs and Stability of a High-Level Ciprofloxacin Resistance Phenotype in Salmonella enterica Serotype Enteritidis: Reduced Infectivity Associated with Decreased Expression of Salmonella Pathogenicity Island 1 Genes , 2009, Antimicrobial Agents and Chemotherapy.

[7]  D. Hughes,et al.  Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness , 2009, PLoS pathogens.

[8]  A. Jerse,et al.  Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice. , 2008, Vaccine.

[9]  Douglas M. Warner,et al.  Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC‐MtrD‐MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness , 2008, Molecular microbiology.

[10]  Yanpeng Ding,et al.  NorB, an Efflux Pump in Staphylococcus aureus Strain MW2, Contributes to Bacterial Fitness in Abscesses , 2008, Journal of bacteriology.

[11]  S. Gillespie,et al.  Fluoroquinolone-Resistant Mutants of Burkholderia cepacia , 2007, Antimicrobial Agents and Chemotherapy.

[12]  Douglas M. Warner,et al.  Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. , 2007, The Journal of infectious diseases.

[13]  Anna A. Vickers,et al.  Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. , 2007, The Journal of antimicrobial chemotherapy.

[14]  B. Levin,et al.  Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.

[15]  D. Andersson The biological cost of mutational antibiotic resistance: any practical conclusions? , 2006, Current opinion in microbiology.

[16]  Lei Wu,et al.  Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. , 2006, The Journal of antimicrobial chemotherapy.

[17]  K. Workowski,et al.  Sexually transmitted diseases treatment guidelines, 2006. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  Hong Wu,et al.  α-2,3-Sialyltransferase Enhances Neisseria gonorrhoeae Survival during Experimental Murine Genital Tract Infection , 2006, Infection and Immunity.

[19]  P. McDermott,et al.  Fitness of antimicrobial-resistant Campylobacter and Salmonella. , 2006, Microbes and infection.

[20]  M. Lipsitch,et al.  Incremental increase in fitness cost with increased beta -lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. , 2006, The Journal of infectious diseases.

[21]  John W Tapsall,et al.  Antibiotic resistance in Neisseria gonorrhoeae. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. Sandvang,et al.  Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections , 2005, Antimicrobial Agents and Chemotherapy.

[23]  O. Sahin,et al.  Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Hayashi,et al.  High Occurrence of Simultaneous Mutations in Target Enzymes and MtrRCDE Efflux System in Quinolone-Resistant Neisseria gonorrhoeae , 2004, Sexually transmitted diseases.

[25]  J. Yuenger,et al.  Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. , 2004, The Journal of infectious diseases.

[26]  S. Eriksson,et al.  Fusidic Acid-Resistant Mutants of Salmonella enterica Serovar Typhimurium with Low Fitness In Vivo Are Defective in RpoS Induction , 2003, Antimicrobial Agents and Chemotherapy.

[27]  Lori A. S. Snyder,et al.  A Gonococcal Efflux Pump System Enhances Bacterial Survival in a Female Mouse Model of Genital Tract Infection , 2003, Infection and Immunity.

[28]  Gale R. Burstein,et al.  Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.

[29]  F. Tubau,et al.  Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae , 2003, Antimicrobial Agents and Chemotherapy.

[30]  H. Lo,et al.  Molecular mechanisms of fluoroquinolone resistance. , 2003, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[31]  O. Berg,et al.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Ruiz,et al.  Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. , 2001, The Journal of antimicrobial chemotherapy.

[33]  D. Trees,et al.  Molecular Epidemiology of Neisseria gonorrhoeae Exhibiting Decreased Susceptibility and Resistance to Ciprofloxacin in Hawaii, 1991–1999 , 2001, Sexually transmitted diseases.

[34]  D. Andersson,et al.  Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus , 2001, Molecular microbiology.

[35]  A. Jerse Experimental Gonococcal Genital Tract Infection and Opacity Protein Expression in Estradiol-Treated Mice , 1999, Infection and Immunity.

[36]  W. Whittington,et al.  Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and the United States. , 1999, International journal of antimicrobial agents.

[37]  D. Fleming,et al.  From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.

[38]  W. Shafer,et al.  Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Yasuda,et al.  Fluoroquinolone Treatment Failure in Gonorrhea: Emergence of a Neisseria gonorrhoeae Strain With Enhanced Resistance to Fluoroquinolones , 1997, Sexually transmitted diseases.

[40]  D. Stein,et al.  Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant ofNeisseria gonorrhoeae , 1996, Molecular and General Genetics MGG.

[41]  W. Whittington,et al.  Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin , 1995, Antimicrobial agents and chemotherapy.

[42]  W. Shafer,et al.  Transcriptional control of the mtr efflux system of Neisseria gonorrhoeae , 1995, Journal of bacteriology.

[43]  B. Spratt,et al.  Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. , 1995, Microbiology.

[44]  W. M. Huang,et al.  Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone‐resistant isolates , 1994, Molecular microbiology.

[45]  K. Workowski,et al.  Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  I. Kobayashi,et al.  Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. , 2006, International journal of antimicrobial agents.

[47]  Hong Wu,et al.  Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection. , 2006, Infection and immunity.